<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Nov. 7, 2019 (HealthDay News) — Microvascular endothelial dysfunction is associated with an increased risk for solid-tumor cancer, according to a study published online Oct. 31 in the European Journal of Preventive Cardiology<\/i>.<\/p>\n
Takumi Toya, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the predictive value of microvascular endothelial dysfunction for future risk for solid-tumor cancer in 488 patients who underwent microvascular endothelial function assessment using reactive hyperemia peripheral arterial tonometry.<\/p>\n
The researchers found that 9.5 and 3.7 percent of patients with a baseline reactive hyperemia peripheral arterial tonometry index \u22642.0 (defined as microvascular endothelial dysfunction) and >2.0, respectively, were diagnosed with incident solid-tumor cancer during follow-up. Compared with patients with a reactive hyperemia peripheral arterial tonometry index >2.0, those with a reactive hyperemia arterial tonometry index \u22642.0 had lower solid-tumor cancer-free survival during a median follow-up of six years. The incidence of solid-tumor cancer was predicted by reactive hyperemia peripheral arterial tonometry index \u22642.0, with a hazard ratio of 2.52 after adjustment for age, sex, and coronary artery disease. Hazard ratios were 2.83 after adjusting for diabetes mellitus, hypertension, smoking status, and body mass index >30 kg\/m\u00b2; 2.79 after adjusting for fasting plasma glucose, systolic blood pressure, smoking status (current or former), and body mass index; and 2.43 after adjusting for the Framingham risk score.<\/p>\n
“This abnormal vasoreactivity should alert clinicians not only to the risk of cardiovascular disease but to malignancy, as well,” a coauthor said in a statement. “This risk prediction appears to precede the development of disease by more than five years.”<\/p>\n
One author disclosed financial ties to Itamar Medical.<\/p>\n